Navigation Links
Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Date:9/23/2009

RICHMOND, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania. Both Phase 1 studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic(TM) approach, however subjects' CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden will also be monitored.

"Opening a second Phase 1 clinical trial of this exciting new approach to HIV/AIDS treatment enables us to expedite clinical and commercial development of SB-728-T. We are very pleased with the FDA's decision enabling us to expand this program and move forward quickly with a repeat-dosing trial," said Dale Ando, M.D., Sangamo's chief medical officer and vice president of therapeutic development.

"The best approach to controlling HIV is by preventing infection of cells in the first place. Since 1996, when CCR5 was validated as a target for HIV therapy, the goal has been to recapitulate the naturally-occurring protection against viral infection exhibited by individuals who have the CCR5-delta32 mutation. We have the ability to disrupt the CCR5 gene and make human T-cells resistant to infection by CCR5-specific strains of HIV. In this trial we will be evaluating SB-728-T in subjects that have well-controlled levels of virus but have sub-optimal recovery of CD-4+ T-cell counts despite long-term triple drug therapy. This group represents approximately thirty per
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
2. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
3. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
7. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
8. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
9. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
10. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
11. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... Dec. 22, 2014   TRU-D SmartUVC LLC, ... disinfection robot, announced today that the General Services Administration ... November 2019.   This newly formed agreement ... levels of government purchasers, including Department of Veteran Affairs ... Homeland Security contacts purchasing solutions for the Ebola effort ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
(Date:12/24/2014)... For chic ladies, new fashionable outfits are necessary ... their Holiday Wish List, Angeldress.co.uk has chosen some ... accent ladies’ holiday wardrobe by launching a promotion on its ... the discount of 80% off, like a cheap suit. , ... company’s chic wedding dresses are among the hottest items in ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... regards to the various market dynamics such as the ... assisted arthroscopy, the wait time for U.S. sports medicine, ... medicine market, and the challenges faced by the market. ... http://www.researchmoz.us/global-sports-medicine-market-report-2014-edition-report.html , The report also provides an overview ...
(Date:12/24/2014)... Plantation, FL (PRWEB) December 24, 2014 ... permanent solution for a tooth replacement. They offer the ... boast several advantages over other forms of tooth replacement. ... not rely on the adjacent teeth for support, and ... many people have been told that they are not ...
(Date:12/24/2014)... Viejo, California (PRWEB) December 24, 2014 ... release of the ProDenoise from Pixel Film Studios. , “The ... noise or grain in their footage,” said Christina Austin, CEO ... have in any Final Cut Pro X editors toolbox.” , ... film noise or grain in their footage with ProDenoise from ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... good news about the experimental Ebola vaccine that U.S. officials ... shows a precursor of that vaccine produced a safe ... of the vaccine, when given to more than 100 Ugandans ... white blood cells that could potentially protect a person against ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4
... Amanda Gardner HealthDay Reporter , TUESDAY, April ... the middle ground with its new drug control policy, ... Tuesday, rejects both the harsh "war on drugs" ... the push to legalize illegal drugs. Gil Kerlikowske, ...
... HOUSTON - Scientists who developed a technology for identifying and ... have found a way to penetrate the outer membrane and ... the cell. In a paper published today online in ... The University of Texas MD Anderson Cancer Center reports packaging ...
... , TUESDAY, April 17 (HealthDay News) -- The ... apparently because of changes in the brain,s white matter, a ... aged 21 to 85, to perform a learning task involving ... that age-related declines in decision-making are associated with the weakening ...
... , TUESDAY, April 17 (HealthDay News) -- ... reduce the spread of the AIDS-causing virus, but would ... high risk for HIV infection, according to a new ... to analyze the use of the combination drug tenofovir-emtricitabine ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, April ... patients, own tumor cells led to a nearly 50 percent ... the same malignancy that claimed the life of U.S. Sen. ... multicenter trial of about 40 patients with recurrent glioblastoma -- ...
... bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell ... in 2006 did not lead to significantly increase survival ... Medicare, a new study by Dana-Farber Cancer Institute researchers has ... 18 Journal of the American Medical Association , a ...
Cached Medicine News:Health News:White House Drug Policy Shifts Strategy 2Health News:White House Drug Policy Shifts Strategy 3Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 2Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 3Health News:HIV Prevention Pill Cost-Effective for High-Risk Men: Study 2Health News:Brain Tumor Vaccine Shows Promise in Early Trial 2Health News:Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients 2
... The SkanWasher 400 is ... microplate washer with built-in ... The individual pressure settings ... very gentle wash to ...
Lab-Reader...
Fully automatic NRTL and CE certified microplate reader....
... a compact and versatile multilabel ... design allows up to six ... counting, luminescence, absorbance, and fluorescence ... and fluorescence polarization all on ...
Medicine Products: